Global Pneumonia Therapeutics Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028
“Global Pneumonia Therapeutics Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028” is a recent report generated by MarketResearch.biz. The global pneumonia therapeutics market report has been segmented on the basis of therapeutics, distribution channel, and region.
Global Pneumonia Therapeutics Market: Overview
Pneumonia is a form of acute respiratory infection that affects the lungs. Individual having pneumonia alveoli are filled with pus and fluid which makes breathing painful and limits oxygen intake. Pneumonia is most frequent infectious disease worldwide causing incredible socio-economic burden developed and developing countries. In addition, pneumonia is leading infectious cause of death in children worldwide accounting for 15% of all deaths of children under age of 5 years. Importantly, despite appropriate antibiotic treatment 14–35% of all hospitalized community-acquired pneumonia (CAP) patients die depending on age and comorbidities.
Global Pneumonia Therapeutics Market: Dynamics
Rising prevalence of pneumonia across the globe and increasing development of adjuvant therapeutic strategies in addition to antibiotics are some major factors expected to expected to drive growth of the global market. According to World Health Organization Pneumonia killed 920 136 children under age of 5 in 2015, accounting for 16% of all deaths of children under five years old.
In addition, increasing healthcare expenditure by the government of developing countries in order to facilitate advanced healthcare facilities is another factor expected to support growth of the global market.
Moreover, increasing number of ongoing clinical trials for development of vaccines and drug molecules is another factor expected to further boost growth of the target market to certain extent.
However, low awareness and limited access to therapy are major factors expected to hamper growth of the global market.
Increasing investment for technological advancements and R&D activities for development of vaccines are factors expected to create potential revenue opportunities in terms of revenue for players operating in the target market over the forecast period. In addition, increasing public-private partnership for R&D activities is expected to further support growth of the market to certain extent.
Global Pneumonia Therapeutics Market: Segment Analysis
Among the therapeutics segments, the prevention vaccines segment is expected to dominate in the target market over the forecast period.
Among the distribution channel segments, the hospitals segment is expected to dominate in the target market over the forecast period.
Global Pneumonia Therapeutics Market: Region
The markets in North America and Europe are expected to contribute significant revenue shares in the global market. This can be attributed to well-developed healthcare infrastructure, increasing prevalence’s of community-acquired pneumonia, and presence of major players operating in the target market across various countries in this region. According to National Center for Biotechnology Information, an estimated 1.3 Mn annual cases of community-acquired pneumonia (CAP) occur among adults aged 65 years and older in the US. In addition, growing merger and acquisition activities between regional and international players is expected to further support growth of the target market in this region.
The market in Asia Pacific is expected to witness fastest growth, owing to increasing government expenditure on healthcare infrastructure and presence of prominent players operating in the emerging economies such as India and China in this region.
Global Pneumonia Therapeutics Market Segmentation
Segmentation by therapeutics:
- Prevention Vaccines
- Treatment Drugs
Segmentation by distribution channel:
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
Segmentation by region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2017 Estimated Year 2018 Forecast Period 2018–2027 Revenue in US$
- GlaxoSmithKline plc
- Sanofi SA
- Merck & Co. Inc.
- Novartis AG
- Eli Lilly and Company
- AstraZeneca PLC
- Pfizer Inc.
- Baxter International Inc.,
- Allergan plc
- Lupin Pharmaceuticals Inc.
Request for TOC
Request for Customization
Don't just take our word. We are trusted by these great companies!